Pad­cev-Keytru­da sets new stan­dard in blad­der can­cer as Seagen and Astel­las move to­ward full ap­proval: #ES­MO23

MADRID — Thou­sands of ES­MO del­e­gates on Sun­day gave a stand­ing ova­tion to con­fir­ma­to­ry tri­al da­ta show­ing Seagen and Astel­las Phar­ma’s Pad­cev in com­bi­na­tion with Mer­ck’s Keytru­da is the “new stan­dard of care” in first-line blad­der can­cer.

Da­ta from the study showed that the com­bo can es­sen­tial­ly dou­ble over­all sur­vival and pro­gres­sion-free sur­vival com­pared with chemother­a­py. And it did so in a wider group of pa­tients than the drugs are cur­rent­ly ap­proved for, which Seagen be­lieves could al­most dou­ble the el­i­gi­ble pa­tient pop­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER